HC-010(Shanghai Hongcheng)

N/A

Report date: 2026/03/19 20:00:18

Base Information

Drug NameHC-010(Shanghai Hongcheng)

Drug Alias NameHC-010HC010

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody

Mechanisms of ActionProgrammed cell death protein 1 blockersCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsVascular endothelial growth factor inhibitors

TargetsProgrammed cell death protein 1Cytotoxic T-Lymphocyte-Associated Antigen 4Vascular endothelial growth factor

Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesHC Biopharma Inc

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHC Biopharma Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung

Inactive IndicationsN/A

Other Information

ATC CodeN/A